Ticker League

Ovid Therapeutics (OVID) Free Cash Flow Bridge

Pinpoint what moved Ovid Therapeutics's free cash flow from TTM through Q1 2025 to TTM through Q1 2026 — operating cash flow shifts and capex changes, each driver sized in dollars.

TTM

FCF YoY

+15.42%

OCF YoY

+15.33%

Capex Change

-52.0K

FCF Conversion Δ

Free cash flow bridge for Ovid Therapeutics (OVID) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Free cash flow: $7.65M

FCF bridge breakdown for Ovid Therapeutics (OVID) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Free Cash Flow−$49.60M
  • Operating Cash Flow$7.60M
  • Capital Expenditure$52.00K
  • Free Cash Outflow−$41.95M
Identity check: drivers reconcile to ΔNI within $0.00
Want to see how cash flow is built up?Cash Flow Waterfall

Frequently asked questions

Data & methodology

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation